Original Research

Effects of esketamine combined with dexmedetomidine on postoperative delirium and quality of recovery in elderly patients undergoing thoracoscopic radical lung cancer surgery: a randomized controlled trial

Cong-Li Zhang[1], Yan Yan[1#], Yang Zhang[1#], Han-Lin Bai[1], Qin Zhuang[1], Nan-Nan Song[1], Chuan-Jiang Feng[1], Li-Juan Xie[1], Si-Yi Wang[1], Xiao-Hong Li[1], Di Liu[1] and Li Ren[2] [ID]

[1]Department of Anesthesiology, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China and [2]School of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China

Abstract

Objective. This study aimed to investigate the effects of esketamine (Esk) combined with dexmedetomidine (Dex) on postoperative delirium (POD) and quality of recovery (QoR) in elderly patients undergoing thoracoscopic radical lung cancer surgery.

Methods. In this prospective, randomized, and controlled study, 172 elderly patients undergoing thoracoscopic radical lung cancer surgery were divided into two groups: the Esk + Dex group (n = 86) and the Dex group a (n = 86). The primary outcome was the incidence of POD within 7 days after surgery and the overall Quality of Recovery−15 (QoR − 15) scores within 3 days after surgery. Secondary outcomes included postoperative adverse reactions, extubation time, PACU stay, and hospitalization time. Serum levels of IL-6, IL-10, S100β protein, NSE, $CD3^+$, $CD4^+$, and $CD8^+$ were detected from T0 to T5.

Results. Compared with the Dex group, the incidence of POD in the Esk + Dex group was significantly lower at 7 days after surgery (14.6% vs 30.9%; P = 0.013). The QoR − 15 score was significantly increased 3 days after surgery (P < 0.01). Levels of IL-6 and $CD8^+$ were significantly decreased, and IL − 10 levels were significantly increased at T1-T2 (P < 0.05). At T1-T4, NSE levels were significantly decreased, while $CD3^+$ and $CD4^+/CD8^+$ values were significantly increased (P < 0.01). At T1-T5, serum S100β protein concentration decreased significantly, and $CD4^+$ value increased significantly (P < 0.01). The incidence of nausea/vomiting and hyperalgesia decreased significantly 48 hours after surgery (P < 0.01). The duration of extubation, PACU stay, and postoperative hospitalization were significantly shortened.

Conclusions. Esketamine combined with dexmedetomidine can significantly reduce the POD incidence and improve the QoR in patients undergoing thoracoscopic radical lung cancer surgery, which may be related to the improvement of cellular immune function.

Introduction

Postoperative delirium (POD) is a clinical syndrome caused by acute brain dysfunction or encephalopathy, characterized by changes in attention and cognition, such as hypoactivity, lethargy, and mental disorders.[1] Although a series of interventions have been adopted clinically to reduce the occurrence of POD, recent studies have shown that the incidence of POD in elderly patients was still between 5.1–43.8%.[2–6] Compared with traditional thoracotomy, thoracoscopic lung surgery can greatly reduce postoperative pain, shorten hospital stay, and improve patients' quality of life, but the incidence of POD is still high, and its high incidence and disability rate bring serious adverse effects on families and society.[7–9] Therefore, it is an urgent problem to reduce the POD incidence and improve the quality of postoperative recovery.

Esketamine (Esk), as the right isomer of ketamine, has a strong analgesic effect mainly through non-competitive blocking of the N-methyl-D-aspartic acid (NMDA) receptor. At present, it has been widely used in intraoperative and postoperative analgesia.[10, 11] In recent years, esketamine has been used more and more prophylactically in clinical studies of anti-depression and anti-suicide.[12, 13] Basic studies have confirmed that esketamine mainly reduces the incidence of perioperative depression, cognitive dysfunction, delirium, and vital organ injury through anti-inflammatory, antioxidant, anti-apoptosis, autophagy, and other mechanisms.[14, 15] In addition, a clinical study showed that esketamine administration enhanced the quality of recovery by alleviating postoperative pain.[16, 17] When POD occurs in elderly patients after

surgery, the cellular immune function often changes significantly. However, it has not been reported whether esketamine improves cellular immune function while reducing POD and improving the postoperative quality of recovery (QoR) of patients.

Dexmedetomidine (Dex), a highly selective adrenergic α2 receptor agonist, offers sedative, analgesic, anti-inflammatory, organ protective, and cognitive enhancing effects, making it widely utilized in perioperative and ICU settings.[18, 19] While esketamine presents significant clinical advantages, it may also induce mental symptoms such as headache, dizziness, hallucinations, nightmares, and irritability. The expert consensus on preventing and treating postoperative delirium in elderly Chinese patients explicitly states that esketamine alone is not recommended for reducing the risk of POD in elderly patients, however, the combined use of dexmedetomidine may be beneficial.[20] Therefore, in clinical practice, dexmedetomidine is frequently employed as an adjunctive medication during the perioperative period in conjunction with esketamine. However, the effect of esketamine combined with dexmedetomidine on the postoperative POD and QoR in patients undergoing thoracoscopic radical lung cancer surgery remains unknown.

This study aims to explore the effects of esketamine combined with dexmedetomidine on POD, QoR, and cellular immunity in elderly patients undergoing thoracoscopic radical lung cancer surgery. It is expected to provide a new theoretical basis and research target for reducing POD in elderly patients.

Materials and methods

Ethics and study design

This prospective, randomized, double-blind, controlled clinical study has been approved by the Clinical Medical Research Ethics Committee of Bengbu Medical University (Approval No. 2023211) and registered in the Chinese Clinical Trial Center (No. ChiCTR2100051804). This study was conducted in strict accordance with the ethical requirements set out in the Declaration of Helsinki, the International Ethical Guidelines for Biomedical Research Involving Humans, and the Measures for the Ethical Review of Biomedical Research Involving Humans formulated by the Ministry of Health of China. Consent was obtained from the patients and their families the day before surgery, and informed consent for anesthesia and the program was signed.

This study enrolled 176 elderly patients undergoing thoracoscopic radical lung cancer surgery from August 2023 to May 2024. Inclusion criteria: *a)* Age 65–80 years old, BMI 18–30 kg/m^2, American Society of Anesthesiologists (ASA) grade II or III; *b)* The patient was diagnosed with lung cancer based on pathological examination or was strongly suspected of having lung cancer after thorough analysis of imaging studies, tumor-related biomarkers, and clinical symptoms; *c)* Patients can tolerate thoracoscopic radical lung cancer surgery under general anesthesia after evaluation.

Exclusion criteria: *a)* Combined with other malignant tumors; *b)* Prior to the operation, there were mental abnormalities, psychological disorders, neurocognitive disorders, central nervous system diseases, or a history of stroke; *c)* Accompanied by immune dysfunction; *d)* Received preoperative chemoradiotherapy, immunization, or targeted therapy; *e)* Allergic to esketamine or contraindicated in esketamine use; *f)* There is a vertical spinal plane block contraindicated; *g)* The presence of heart, liver, and kidney dysfunction or other serious complications; *h)* Only thoracoscopic cuneiform lobectomy, conversion to thoracotomy, or urgent re-operation is required after surgery; *i)* Intraoperative hemorrhage or allogeneic blood

transfusion; *j)* Recurrent or metastatic lung cancer; *k)* Although lung cancer was highly suspected before surgery, the pathological results were benign; *l)* Refusing to sign informed consent.

Randomization and blinding

A total of 172 patients were randomly divided into the Esk + Dex group and the Dex group by an online randomization tool (Sealed Envelope Ltd.2022.), with 86 cases in each group. The randomization utilized a 1:1 ratio with block sizes of 2 and 4, generating 172 unique alphanumeric codes. The randomly generated codes were placed into opaque envelopes and locked by intraoperative data collectors. They were responsible for preparing and distributing either esketamine solution or normal saline based on the randomized results. The intraoperative portion of the case report form was completed by these collectors. Esketamine solution or normal saline were prepared with syringes to 20 mL (for induction) and 50 mL (for maintenance), respectively, with only randomly generated codes labeled on the syringes. Post-operative visitors deliberately ignored trial grouping and interventions. At the end of all trials, the group assignment was not known until the codes on the envelopes matched those on the syringes. In order to avoid bias caused by subjective factors of subjects and investigators, subjects, anesthesiologists, surgeons, and nursing staff were unaware of the grouping status and the contents of syringes. Statistical analysis of test data was performed independently by designated statisticians.

Study interventions

Patients in both groups received a dexmedetomidine infusion (0.5 μg/kg loading dose was pumped starting) 15 minutes before anesthesia induction, and the infusion was completed 10 minutes later. The infusion was continued at a pump rate of 0.4 μg/kg/h until 30 minutes before the end of surgery). Esk + Dex group: 0.25 mg/kg esketamine was intravenously injected during anesthesia induction, followed by continuous infusion at a pumping rate of 0.125 mg/kg/h until 30 minutes before the end of surgery. Dex group: the same volume of normal saline was infused in the same way.

Anesthesia protocol

Anesthesia induction was performed using midazolam 0.05–0.1 mg/kg, etomidate 0.2–0.3 mg/kg, sufentanil 0.3–0.5 μg/kg, and rocuronium 1–1.5 mg/kg. After induction of anesthesia, the bronchial catheter was intubated under the guidance of a fiber-bronchoscope. Then, the erector spinae plane block (ESPB) was performed by anesthesiologists under the guidance of ultrasound using 15-20 ml 0.25%–0.5% ropivacaine. Anesthesia maintenance was performed using continuous intravenous infusions of propofol (2.5–5 mg/kg/h), remifentanil (2–5 μg/kg/h), rocuronium (1–1.5 mg/kg/h) and dexmedetomidine. Sufentanil was injected intravenously (1–1.5 μg/kg/ time). BIS value was maintained at 40–60, mean arterial pressure (MAP) at 65–100 mmHg (no more than 20% of the baseline value), and heart rate at 60–80 beats /min during operation. After surgery, all patients were transported to PACU for recovery. After the patient was awake, a self-controlled electronic analgesia pump was connected intravenously to relieve pain. Analgesic pump formulation: 0.5–1 μg/kg sufentanil +0.3–0.5 mg/kg dezocine +0.1–0.2 mg/kg tropisetron, diluted with normal saline to 100 mL; Operation parameters: loading dose 3 mL, continuous infusion rate 2 ml/h, single dose 3 mL, locking time 15 min.

Data collection

Baseline data
Age, sex, height, weight, smoking status, ASA grade, comorbidities (hypertension, diabetes, coronary heart disease, cerebral infarction) and education level were recorded. The preoperative respiratory (PaO_2, $PaCO_2$ and SpO_2) and circulatory (MAP, HR and Hb) function indexes were monitored. The Mini-mental State Examination (MMSE) was used to evaluate the cognitive function of patients 1 day before surgery; the QoR-15 was used to evaluate the basic score of patients 1 day before surgery.

Intraoperative parameters
The MAP, HR, and SPI of the two groups were monitored at the time of tracheal intubation, skin incision, 30 min, 60 min, and the end of the operation. The consumption of propofol, sufentanil, remifentanil, esketamine, and dexmedetomidine during the operation and the concentration of end-expiratory sevoflurane at the time of incision, 30 min, and 60 min of operation were recorded. Intraoperative fluid infusion (crystal and colloid), blood loss, urine volume, and the number of norepinephrine administrations were recorded. The occurrence of hypoxemia (PaO_2 < 60 mmHg or SpO_2 < 90% for ≥1 min), hypotension, hypertension, tachycardia, and bradycardia were recorded. Hypotension/hypertension was defined as a decrease/increase in systolic blood pressure exceeding 30% of the baseline value for ≥1 min; Tachycardia/bradycardia refers to a heart rate of more than 100/ less than 50 beats /min for ≥1 min.

Postoperative parameters
Incidence of POD within 7 days after surgery, QoR-15 score within 3 days after surgery, adverse reactions and safety results (nausea/vomiting, rest/cough pain, hyperalgesia, pruritus, headache/dizziness, hallucination/nightmare, agitation, delayed recovery, etc.), patient satisfaction, postoperative complications, pathological type, operation time, postoperative tracheal catheter removal time, PACU stay time, and postoperative hospital stay of the two groups were recorded.

The 3D-CAM scale was used to evaluate the occurrence and severity of POD,[21] and the incidence of POD was calculated by the number of POD cases. POD assessments were completed by the blind evaluator at the bedside during the hospital period, and the remaining days of hospitalization less than 7 days after surgery were mainly through telephone follow-up. QoR scores were assessed once in the morning and afternoon every day, and the average value was taken. Delayed recovery refers to the inability to open eyes and shake hands for more than 30 minutes after surgery and no obvious response to pain stimuli. Pain assessment was performed by NRS score: when NRS >5, flurbiprofen axetil (50 mg/time) was injected intravenously as a rescue analgesic measure.

Detection of inflammatory response, brain function and cellular immune function
Peripheral blood was collected before anesthesia induction (T0), at the end of surgery (T1), 12 h after surgery (T2), 24 h after surgery (T3), 48 h after surgery (T4), and 72 h after surgery (T5). The serum levels of S100β protein, NSE, IL-6, and IL-10 were determined by enzyme-linked immunosorbent assay (ELISA, Nanjing Jiancheng, China). The $CD3^+$, $CD4^+$, and $CD8^+$ were determined by flow cytometry (CytoFLEX LX flow cytometry, Beckman Coulter, USA), and the $CD4^+/CD8^+$ ratio was calculated.

Outcomes
Primary outcomes: the incidence of POD within 7 days after surgery and QoR within 3 days after surgery. Secondary outcomes: the consumption of propofol, sufentanil, and remifentanil during operation, end-expiratory concentration of sevoflurane, postoperative nausea/vomiting, hyperalgesia, headache/dizziness, hallucinations/nightmares, and other adverse reactions; postoperative extubation time, PACU stay time, and postoperative hospitalization time.

Sample size
The sample size was estimated using the PASS 15.0 version of statistical software. A prospective study showed that the incidence of POD in elderly patients was 43.8%.[5] We hypothesized that esketamine would reduce the incidence of POD from 43.8% to 21.9% (that is a relative reduction of 50%). The parameters were set as follows: α =0.05, 1-β = 0.80, control rate value = 0.438, test rate value = 0.219, test:Nc sample size = 1:1. The estimated sample size was N = 160 (n = 80 each group). Anticipating a potential 10% loss to follow-up due to surgical or patient-related factors, we aimed to enroll a total of 176 subjects, with 88 in each group.

Statistical analysis
SPSS 25.0 statistical software was used to analyze and process the data. Normal distribution data were represented as mean (SD), and an independent sample t test was used for comparison between groups. The non-normal distribution data were represented as median (IQR), and the Mann–Whitney U rank sum test was used for comparison between groups. Categorical variables were expressed as n (%), and the $\chi 2$ test or Fisher exact test was used for comparison between groups. The intervention effects of Esk + Dex vs Dex were assessed using the odds ratio (OR) or median difference (MD) with its 95% confidence interval (CI). $P < 0.05$ was considered a significant difference.

Results

Patient recruitment
A total of 176 elderly patients scheduled for elective thoracoscopic radical lung cancer surgery were screened for eligibility. Four patients were excluded due to non-compliance with inclusion criteria (n = 2) and refusal to participate (n = 2). Thus, 172 patients met the inclusion criteria. The patients were randomly divided into the Esk + Dex group (n = 86) and the Dex group (n = 86). Of the 172 patients, 9 cases were excluded due to cancellation of surgery (n = 2), withdrawal at the patient's request (n = 1), conversion to thoracotomy (n = 1), and benign pathologic findings (n = 5), respectively. Finally, a total of 163 patients received the specified intervention and were included in the analysis, including 82 in the Esk + Dex group and 81 in the Dex group (Figure 1).

Perioperative and intraoperative data
The demographic and baseline data characteristics of the two groups were well balanced, and the difference was not statistically significant (all P > 0.05, Table 1). The preoperative respiratory (PaO_2, $PaCO_2$ and SpO_2) and circulatory (MAP, HR and Hb) function monitoring indexes, MMSE, and QoR-15 scale scores

Figure 1. Flowchart of patient recruitment. Esk, esketamine; Dex, dexmedetomidine.

1 day before surgery were in the normal range, and there was no significant difference(all P > 0.05, **Table 1**). Compared with the Dex group, the intraoperative consumption of propofol, sufentanil, and remifentanil and the end-expiratory concentration of sevoflurane were significantly decreased in the Esk + Dex group (all P < 0.05). There were no significant differences between the two groups in the amount of fluid in and out during the operation, the intervention times of norepinephrine, and the incidence of intraoperative hypotension, tachycardia, and bradycardia, and no intraoperative hypoxemia and hypertension were found between the two groups (all P > 0.05, **Table 2**).

Clinical outcomes

Compared with the Dex group, the incidence of POD within 7 days after surgery was significantly decreased in the Esk + Dex group (14.6% vs 30.9%, P = 013). POD mainly occurred in the first 3 days after surgery, especially on the 2nd and 3rd days. The QoR-15 score was significantly higher within 3 days after surgery (P < 0.05). The incidence of nausea/vomiting and hyperalgesia was significantly reduced 48 hours after surgery; 5 cases in the Dex group needed to be treated with antiemetic drugs, while no intervention was required in the Esk + Dex group. Postoperative tracheal catheter removal time, PACU stay time, and postoperative hospital stay were significantly shortened (all P < 0.05). There were no significant differences in the incidence of NRS score, skin pruritus, headache/dizziness, hallucinations/nightmares, agitation, and delayed recovery between the two groups 48 hours after surgery (all P > 0.05). There were no obvious postoperative complications in the two groups (P > 0.05, **Table 3**).

Indicators of inflammatory response, brain injury, and cellular immune function

The levels of IL-6, IL-10, S100β protein, and NSE increased gradually in both groups after surgery. S100β protein and NSE levels peaked at T2, IL-6 concentration reached its highest point at T3, and IL-10 concentration peaked at T4. In comparison to the Dex group, the Esk + Dex group exhibited significantly decreased serum IL-6 levels and increased IL-10 levels at T1-T2 (all P < 0.05), reduced serum S100β protein concentration at T1-T5 (all P < 0.01), and decreased NSE levels at T1-T4 (all P < 0.01, **Figure 2**). The values of $CD3^+$, $CD4^+$, $CD8^+$, and $CD4+/CD8^+$ declined progressively in both groups postoperatively, with $CD3^+$ and $CD4^+/CD8^+$ reaching their lowest points at T3, $CD8^+$ at T1, and $CD4^+$ at T3. Compared to the Dex group, the Esk + Dex group exhibited significantly increased proportions of $CD3^+$ and $CD4^+/CD8^+$ at T1-T4 (all P < 0.01), increased $CD4^+$ proportion at T1-T5 (all P < 0.05), and decreased $CD8^+$ proportion at T1-T2 (all P < 0.01, **Figure 3**).

Discussion

Nerve block techniques have been routinely implemented in thoracoscopic surgery with definite effects.[22–25] Erector spinae plane block has the advantages of exact block effect, simple operation, and high safety, so it has been widely adopted.[23] The affinity of esketamine with the NMDA receptor is 4 times that of levodopa, and the analgesic intensity is 2 times that of racemic ketamine. Esketamine has faster metabolism and faster recovery than racemic ketamine and has a lower incidence of adverse reactions, so it is widely used in clinical practice.[26–28] However, the application of esketamine often causes some psychiatric symptoms and other side effects in patients. Studies have confirmed that combined with dexmedetomidine can achieve good clinical effects.[20] Therefore, in terms of grouping in this study, we did not set up a separate group of esketamine and dexmedetomidine and compared their clinical effects. Instead, both groups were intravenously infused with dexmedetomidine and underwent ultrasonuse-guided erector spinae plane block. The study results indicated that the NRS scores for both resting and coughing states within 48 hours after surgery were consistently low in both groups, with no significant difference. This suggests that regardless of esketamine administration, the combination of dexmedetomidine with erector spinal plane block provided effective postoperative analgesia. Furthermore, there was

Table 1. Demographics and Baseline Characteristics

	Esk + Dex group (n = 82)	Dex group (n = 81)	P-value
Age, median (IQR), y	70 (68–73)	71 (68–73)	0.144
Sex			
Female	44 (53.7%)	39 (48.1%)	0.482
Male	38 (46.3%)	42 (51.9%)	0.482
Weight, median (IQR), kg	62 (56–70)	65 (58.5–71.5)	0.129
Hight, median (IQR), cm	162 (157–169)	163 (158–170)	0.323
BMI, median (IQR), kg/m^2	23.3 (20.8–25.5)	22.6 (20.7–24.5)	0.134
Current smokers	32 (39.0%)	34 (42.0%)	0.701
ASA grade			
II	23 (28.0%)	19 (23.5%)	0.503
III	59 (72.0%)	62 (76.5%)	0.503
Comorbidities			
Hypertension	48 (58.5%)	39 (48.1%)	0.184
Diabetes	24 (29.2%)	15 (18.5%)	0.108
Coronary atherosclerotic heart disease	10 (12.2%)	13 (16.0%)	0.639
Cerebral infarction	25 (30.5%)	22 (27.2%)	0.480
Education level			
Illiteracy	18 (22.0%)	16 (19.8%)	0.730
Primary school	43 (52.4%)	35 (43.2%)	0.238
Junior high school	14 (17.1%)	20 (25.9%)	0.231
Senior high school or above	7 (8.5%)	10 (12.3%)	0.426
Preoperative baseline measurements			
PaO2, median (IQR), mmHg	76 (72–80)	76 (71–80)	0.498
PaCO2, median (IQR), mmHg	39 (37–42)	39 (36–40)	0.390
SpO$_2$, median (IQR), %	97 (96–98)	98 (96–99)	0.414
MAP, mean (SD), mmHg	89.6 (4.7)	88.5 (5.1)	0.131
HR, median (IQR), beats/min	81 (69–89)	80 (71–90)	0.731
Hb, median (IQR), g/L	123 (117–128)	125 (117–129)	0.668
Preoperative 1d MMSE score, median (IQR)	28 (26–29)	28 (26–29)	0.795
Preoperative 1d QoR–15 score, median (IQR)	139 (137–142)	139 (137–141)	0.322

IQR, interquartile range; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ASA, American society of anesthesiologists; MAP, mean blood pressure; HR, heart rate; Hb, hemoglobin; MMSE, mini-mental state examination; QoR-15, the 15-item quality of recovery scale. Data are presented as median (IQR), mean (SD) or n (%).

a notable reduction in the consumption of intraoperative anesthesia drugs (propofol, sufentanil, remifentanil, and sevoflurane) in the combined intervention group. This reduction underscores esketamine's potent analgesic and sedative properties, supporting its status as the preferred choice for non-opioid anesthesia.

The incidence of postoperative POD in elderly patients undergoing thoracoscopic lobectomy is 26.7% or even higher.[8, 29] POD can seriously affect the postoperative QoR of patients, produce a series of adverse outcomes, and even lead to the death of patients. This study showed that the incidence of POD within 7 days after thoracoscopic radical lung cancer surgery in elderly patients with esketamine intervention decreased from 30.9% to 14.6%, and the QoR was significantly improved within 3 days after surgery. As we all know, postoperative nausea, vomiting, and hyperalgesia are common side effects of opioids, and these adverse reactions are significantly reduced after the application of esketamine, which is also an important reason for some scholars to seek opioid-free anesthesia.[11, 30] Headache, dizziness, hallucinations, nightmares, and postoperative agitation are common side effects of esketamine.[31] However, in this study, the incidence of the above adverse reactions was low between the two groups, and there was no significant difference between the two groups, indicating that the side effects of esketamine were significantly reduced, which was mainly related to the combined application of dexmedetomidine. Postoperative extubation time, PACU stay time, and postoperative hospital stay were significantly reduced. This may be mainly due to the significant decrease in the dosage of sufentanil, remifentanil, propofol, and sevoflurane. S100β protein and NSE are the biochemical indexes most closely related to POD and brain injury. The results showed that the levels of serum S100β protein and NSE in the two groups gradually increased at the end of surgery, and the S100β protein concentration of the esketamine intervention group was significantly lower than that of the control group in the first 3 days after surgery. The level of NSE was also lower than that of the control group in the first 2 days after surgery and returned to close to normal on the third day without statistical difference. The results confirmed that thoracoscopic radical lung cancer surgery can cause significant damage to brain function in elderly patients, and esketamine can alleviate this damage.

Surgery can cause changes in the inflammatory and cellular immune functions of patients. IL-6 and IL-10, as well as CD3$^+$, CD4$^+$, and CD8$^+$, play an important role in the immune response induced by acute stress, such as tracheal intubation and surgical trauma.[32] This study showed that esketamine could inhibit the release of IL-6 and promote the release of anti-inflammatory factor IL-10. IL-6 and IL-10 showed statistical differences between the two groups only at T1-T2, which we considered might be related to the clinical pharmacological characteristics of esketamine. At this stage, esketamine had its own unique advantage, and its anti-inflammatory effect was stronger than dexmedetomidine. At 24 hours after surgery, the benefit of esketamine gradually decreased to the point that the anti-inflammatory effect was comparable between the two groups. Recent studies have shown that CD8$^+$ plays an important role in the regulation of brain injury and neurodegenerative diseases.[33] The levels of CD3$^+$, CD4$^+$ and CD8$^+$ reflect the body's ability to regulate cellular immunity. CD4$^+$/CD8$^+$ ratio can directly reflect the cellular immune status of the body. The results of flow cytometry showed that the levels of CD3$^+$, CD4$^+$, and CD4$^+$/CD8$^+$ in the composite group increased significantly within 48 hours after surgery, while the CD8$^+$ in the composite group was significantly lower than that in the control group within 12 hours after surgery, possibly because esketamine could directly or indirectly activate the killing function of CD8$^+$ on target cells. Within 48 hours after surgery, CD4$^+$/CD8$^+$ values in the combined group were significantly higher than those in the Dex group, indicating that esketamine can effectively regulate the cellular immune function of patients and protect the cellular immune destruction of the body.

Table 2. Intraoperative Parameter

	Esk + Dex group (n = 82)	Dex group (n = 81)	OR or MD (95% CI)	*P*-value
MAP, mean (SD), mmHg				
Intubation	94.8 (11.7)	94.4 (10.7)	0 (−4–3)	0.854
Skin incision	92.7 (4.0)	91.3 (5.4)	−1 (−2–0)	0.063
30 min of operation	86.3 (8.0)	87.1 (8.0)	1 (−2–4)	0.489
60 min of operation	87.0 (7.6)	88.1 (7.9)	1 (−1–3)	0.374
End of operation	87.9 (6.8)	87.2 (7.5)	−1 (−3–2)	0.552
HR, median (IQR), beats/min				
Intubation	87 (80–92)	87 (81–95)	1 (−1–4)	0.357
Skin incision	81 (72–88)	81 (74–87)	−1 (−4–2)	0.596
30 min of operation	78 (71–82)	78 (70–85)	0 (−3–3)	0.610
60 min of operation	79 (72–84)	79 (74–86)	1 (−2–4)	0.476
End of operation	76 (71–85)	77 (70–84)	−1 (−3–2)	0.734
SPI, median (IQR)				
Intubation	37 (35–40)	37 (35–39)	0 (−1–1)	0.220
Skin incision	38 (37–40)	39 (37–41)	1 (0–2)	0.200
30 min of operation	35 (33–36)	35 (34–37)	1 (0–1)	0.090
60 min of operation	40 (39–42)	39 (37–41)	−1 (−2–0)	0.285
End of operation	45 (43–47)	46 (44–47)	0 (0–1)	0.977
Anaesthetics and analgesics, median (IQR)				
Propofol, mg	118 (89–141)	135 (105–150)	15 (5–25)	**0.018**
Sufentanil, ug	40 (39–45)	50 (45–50)	5 (5–10)	**0.000**
Remifentanil, mg	0.8 (0.5–1.0)	0.9 (0.6–1.0)	0.1 (0–0.20)	**0.022**
Esketamine, mg	40 (37–44)	–	–	–
Dexmedetomidine, ug	136 (109–159)	129 (98–170)	0 (−13–13)	0.778
End-expiratory concentration of sevoflurane, %				
Skin incision	1.05 (0.83–1.27)	1.12 (0.92–1.61)	0.19 (0.08–0.29)	**0.000**
30 min of operation	0.88 (0.76–0.98)	1.04 (0.90–1.15)	0.16 (0.11–0.21)	**0.000**
60 min of operation	0.69 (0.61–0.79)	1.02 (0.88–1.12)	0.29 (0.24–0.34)	**0.000**
Fluid intake and outflow and vasoactive drugs, median (IQR)				
Intraoperative fluid infusion, mL	1500 (1100–1500)	1500 (1100–1600)	0 (0–100)	0.189
Intraoperative urine volume, mL	300 (200–400)	300 (250–400)	0 (0–0)	0.546
Intraoperative blood loss, mL	200 (100–300)	200 (90–300)	0 (−50–0)	0.173
Number of norepinephrine interventions during the operation	0.5 (0–1.3)	1 (0–1)	0 (0–0)	0.790
Intraoperative safety results				
Intraoperative hypoxemia	0	0	–	1.0
Intraoperative hypotension	2 (2.4%)	1 (1.2%)	2.0 (0.18–22.5)	0.567
Intraoperative hypertension	0	0	–	1.0
Intraoperative tachycardia	2 (2.4%)	3 (3.7%)	0.65 (0.11–4.00)	0.640
Intraoperative bradycardia	4 (4.9%)	2 (2.5%)	2.03 (0.36–11.38)	0.414

IQR, interquartile range; OR, odds ratio; MD, median difference; CI, confidence interval; MAP, mean blood pressure; HR, heart rate; SPI, surgical pleth index. Data are presented as median (IQR), mean (SD) or n (%).

Limitations

This study has some limitations. First of all, this is a single-center clinical study, and only elderly patients undergoing thoracoscopic radical lung cancer surgery in the First Affiliated Hospital of Bengbu Medical University were selected as research objects. Second, erector spinal plane block and dexmedetomidine infusion were routinely performed in both groups, and these two

Table 3. Postoperative Parameters

	Esk + Dex group (n = 82)	Dex group (n = 81)	OR or MD (95% CI)	*P* -value
POD within 7 days after surgery(3D-CAM), %	12 (14.6%)	25 (30.9%)	0.38 (0.18–0.83)	**0.013**
1 d after surger	2 (2.4%)	6 (7.4%)	0.31 (0.06–1.60)	0.134
2 d after surger	5 (6.1%)	9 (11.1%)	0.52 (0.17–1.62)	0.253
3 d after surger	5 (6.1%)	8 (9.9%)	0.59 (0.19–1.90)	0.373
4 d after surger	0	1 (1.2%)	0.99 (0.96–1.01)	0.313
5 d after surger	0	1 (1.2%)	0.99 (0.96–1.01)	0.313
6 d after surger	0	0	–	1
7 d after surger	0	0	–	1
QoR–15 score, median (IQR)				
1 d after surger	85 (83–87)	80 (78–85)	−4 (−5−3)	**0.000**
2 d after surgery	96 (91–101)	90 (88–94)	−5 (−7−4)	**0.000**
3 d after surgery	117 (114–119)	110 (107–113)	−6 (−8−5)	**0.000**
Postoperative adverse reactions and safety results				
Nausea/Vomiting, %	12 (14.6%)	33 (40.7%)	0.25 (0.12–0.53)	**0.000**
0–24 h	12 (14.6%)	23 (28.4%)	0.43 (0.20–0.94)	**0.032**
24–48 h	0	10 (12.3%)	0.88 (0.81–0.95)	**0.001**
Use of remedial antiemetics(0–48 h)	0	5 (6.2%)	0.94 (0.89–0.99)	**0.022**
Pain scores at rest (NRS), median (IQR)				
at 24 h	2 (0–2)	2 (0–3)	0 (0–0)	0.767
at 48 h	0 (0–1)	0 (0–1)	0 (0–0)	0.739
Pain scores while coughing (NRS), median (IQR)				
at 24 h	3 (1–4)	3 (1–4)	0 (0–0)	0.529
at 48 h	1 (1–2)	1 (1–2)	0 (0–0)	0.916
Use of remedial analgesics 0–48 h	0	0	–	1.0
Hyperalgesia	2 (2.4%)	13 (16.0%)	0.13 (0.03–0.60)	**0.003**
Pruritus	1 (1.2%)	3 (3.7%)	0.32 (0.03–3.15)	0.305
Headache/dizziness	7 (8.5%)	6 (8.5%)	1.17 (0.37–3.64)	0.790
Hallucination/nightmare	3 (3.7%)	2 (2.5%)	1.50 (0.24–9.22)	0.660
Agitation	1 (1.2%)	2 (2.5%)	0.49 (0.04–5.49)	0.553
Delayed recovery	0	1 (1.2%)	0.99 (0.096–1.01)	0.313
Postoperative complications (before discharge)				
Transfer to ICU for further treatment	0	0	–	1.0
Incision infection	0	0	–	1.0
Pulmonary infection	0	0	–	1.0
Pulmonary atelectasis	0	0	–	1.0
Cardio-cerebrovascular accident	0	0	–	1.0
Death	0	0	–	1.0
Pathological diagnosis				
Adenocarcinoma	60 (73.2%)	67 (82.7%)	0.57 (0.27–1.21)	0.142
Squamous carcinoma	12 (14.6%)	6 (7.4%)	2.14 (0.76–6.02)	0.141
Others (Pathological type not specified)	10 (12.2%)	8 (9.9%)	1.27 (0.47–3.39)	0.637
Duration of each stage, median (IQR)				
Length of surgery, min	118 (95–140)	120 (90–138)	0 (−10–10)	0.890
Postoperative tracheal catheter removal time, min	35 (30–40)	41 (34–46)	5 (3–8)	**0.000**

Table 3. *Continued*

	Esk + Dex group (n = 82)	Dex group (n = 81)	OR or MD (95% CI)	*P* -value
Length of PACU stay, min	51 (44–57)	57 (50–60)	5 (3–7)	**0.000**
Length of postoperative hospital stay, d	5.5 (5–6)	6 (5–8)	1 (0–2)	**0.000**

IQR, interquartile range; OR, odds ratio; MD, median difference; CI, confidence interval; POD, postoperative delirium; CAM, confusion assessment method; 3D-CAM, 3-Minute diagnostic interview for CAM-defined delirium; QoR-15, the 15-item quality of recovery scale; NRS, numeric rating scales; ICU, intensive care unit; PACU, post anesthesia care unit. Data are presented as median (IQR) or n (%).

Figure 2. Indicators of inflammatory response and brain injury. IL, interleukin; NSE, neuron-specific enolase. Data are expressed as mean±s. Compared with the Dex group, [a]$P < 0.05$, [b]$P < 0.01$.

interventions may have had some influence on the study results. Moreover, because the formulation of esketamine in the postoperative analgesia pump has not yet formed an exact scheme, considering the safety of patients and the postoperative analgesia effect, this study did not apply esketamine to postoperative analgesia. In addition, this study only conducted short-term follow-up on POD and postoperative QoR of patients and did not study their long-term prognosis, outcome, and survival rate. Last but not least, the exact relationship between POD incidence, postoperative QoR, and cellular immune function still needs to be verified by further basic experiments. Therefore, in the future, we will conduct a multi-center, large sample, multi-group, multi-time prospective study and collect long-term postoperative data of patients.

Conclusion

In conclusion, in this study, we found that esketamine combined with dexmedetomidine can significantly reduce the incidence of POD within 7 days after surgery, improve the QoR within 3 days after surgery, improve cellular immune function, reduce brain damage, reduce inflammatory reactions, reduce the consumption of intraoperative anesthetic drugs and reduce postoperative adverse reactions in elderly patients undergoing thoracoscopic radical lung cancer surgery, and it can also shorten the time of tracheal catheter removal, PACU stay, and postoperative hospital stay. The decrease of POD incidence and the improvement of postoperative QoR may be related to the improvement of cellular immune function of patients by esketamine.

Figure 3. Indicators of cellular immune function. Data are expressed as mean±s. Compared with the Dex group, $^a P < 0.05$, $^b P < 0.01$.

Authors' contribution. Conception and design: Zhang CL, Yan Y, Liu D, Ren L.

Implementation of the study: Zhang Y, Bai HL, Song NN, Zhuang Q.

Data collection and collation: Feng CJ, Xie LJ, Wang SY.

Statistical analysis of data: Zhang CL, Yan Y, Ren L.

Data interpretation: Zhang CL, Yan Y, Liu D, Ren L.

Manuscript drafting: Zhang CL, Yan Y.

Manuscript revision: Ren L, Liu D, Li XH.

Final approval of the version to be published: All authors.

References

1. Palanca BJA, Wildes TS, Ju YS, Ching S, Avidan MS. Electroencephalography and delirium in the postoperative period. *Br J Anaesth.* 2017;**119**(2): 294–307. doi: 10.1093/bja/aew475.
2. Li T, Li J, Yuan L, et al. RAGA study investigators. Effect of regional vs general anesthesia on incidence of postoperative delirium in older patients undergoing hip fracture surgery: the RAGA randomized trial. *JAMA.* 2022; **327**(1):50–58. doi: 10.1001/jama.2021.22647. Erratum in: JAMA. 2022 Mar 22;327(12):1188.

3. Chen L, Au E, Saripella A, et al. Postoperative outcomes in older surgical patients with preoperative cognitive impairment: a systematic review and meta-analysis. *J Clin Anesth.* 2022;**80**:110883. doi: 10.1016/j.jcli-nane.2022.110883.

4. Wang W, Yao W, Tang W, Li Y, Lv Q, Ding W. Association between preoperative albumin levels and postoperative delirium in geriatric hip fracture patients. *Front Med (Lausanne).* 2024;**11**:1344904. doi: 10.3389/fmed.2024.1344904.

5. van Norden J, Spies CD, Borchers F, et al. The effect of peri-operative dexmedetomidine on the incidence of postoperative delirium in cardiac and non-cardiac surgical patients: a randomised, double-blind placebo-controlled trial. *Anaesthesia.* 2021;**76**(10):1342–1351. doi: 10.1111/anae.15469.

6. Xiao MZ, Liu CX, Zhou LG, Yang Y, Wang Y. Postoperative delirium, neuroinflammation, and influencing factors of postoperative delirium: A review. *Medicine (Baltimore).* 2023;**102**(8):e32991. doi: 10.1097/MD.0000000000032991.

7. Chen JT, Wu YM, Tiong TY et al., Spectral entropy monitoring accelerates the emergence from Sevoflurane Anesthesia in thoracic surgery: a randomized controlled trial. *J Clin Med.* 2022;**11**(6):1631. doi: 10.3390/jcm11061631.

8. Dongjie Q, Longbiao Z, Peng L et al., Effects of thoracic paravertebral nerve block on postoperative pain and postoperative delirium in elderly patients undergoing thoracoscopic lobectomy. *Medicine (Baltimore).* 2023;**102**(8):e32907. doi: 10.1097/MD.0000000000032907.

9. Lu Y, Yin G, Jin C et al., The application value of esketamine and dexmedetomidine in preventing postoperative delirium and hyperalgesia in elderly patients with Thoracic Anesthesia. *Altern Ther Health Med.* 2024;**30**:AT8067.

10. Chen HY, Meng XY, Gao H et al., Esketamine-based opioid-free anaesthesia alleviates postoperative nausea and vomiting in patients who underwent laparoscopic surgery: study protocol for a randomized, double-blinded, multicentre trial. *Trials.* 2023;**24**(1):13. doi: 10.1186/s13063-022-07003-3.

11. Feng CD, Xu Y, Chen S et al., Opioid-free anaesthesia reduces postoperative nausea and vomiting after thoracoscopic lung resection: a randomised controlled trial. *Br J Anaesth.* 2024;**132**(2):267–276. doi: 10.1016/j.bja.2023.11.008.

12. Ling B, Zhu Y, Yan Z et al., Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial. *BMC Pharmacol Toxicol.* 2023;**24**(1):66. doi: 10.1186/s40360-023-00705-7.

13. Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2022;**21**(6):853–866. doi: 10.1080/14740338.2022.2047928.

14. Wang T, Weng H, Zhou H, et al. Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex. *J Affect Disord.* 2022;**307**:97–107. doi: 10.1016/j.jad.2022.03.072.

15. Yuan J, Chen S, Xie Y, et al. Intraoperative intravenous infusion of esmketamine has opioid-sparing effect and improves the quality of recovery in patients undergoing thoracic surgery: a randomized, double-blind, placebo-controlled clinical trial. *Pain Physician.* 2022;**25**(9):E1389–E1397.

16. Cheng X, Wang H, Diao M, Jiao H. Effect of S-ketamine on postoperative quality of recovery in patients undergoing video-assisted thoracic surgery. *J Cardiothorac Vasc Anesth.* 2022;**36**(8 Pt B):3049–3056. doi: 10.1053/j.jvca.2022.04.028.

17. Jiang G, Wang Y, Liu Q et al., Autophagy: a new mechanism for esketamine as a depression therapeutic. *Neuroscience.* 2022;**498**:214–223. doi: 10.1016/j.neuroscience.2022.05.014.

18. Liu X, Li Y, Kang L, Wang Q. Recent advances in the clinical value and potential of dexmedetomidine. *J Inflamm Res.* 2021;**14**:7507–7527. doi: 10.2147/JIR.S346089. PMID: 35002284;

19. Wiegand A, Behal M, Robbins B, Bissell B, Pandya K, Mefford B. Niche roles for dexmedetomidine in the intensive care unit. *Ann Pharmacother.* 2023;**57**(10):1207–1220. doi: 10.1177/10600280221151170.

20. Anesthesiology Branch of Chinese Geriatrics Society. Chinese expert consensus on prevention and control of elderly patients with postoperative delirium. *Int J Anesth Resus.* 2023;**44**(1):1–27.

21. Mu DL, Ding PP, Zhou SZ et al., Cross-cultural adaptation and validation of the 3D-CAM Chinese version in surgical ICU patients. *BMC Psychiatry.* 2020;**20**(1):133. doi: 10.1186/s12888-020-02544-w.

22. Turhan Ö, Sivrikoz N, Sungur Z, Duman S, Özkan B, Şentürk M. Thoracic paravertebral block achieves better pain control than erector spinae plane block and intercostal nerve block in thoracoscopic surgery: a randomized study. *J Cardiothorac Vasc Anesth.* 2021;**35**(10):2920–2927. doi: 10.1053/j.jvca.2020.11.034.

23. Su P, Kong M, Yang E. Effect of combined erector-spinae plane blocks on the immediate postoperative neuronal and stress biomarkers after thoracoscopic radical resection for lung cancers. *Asian J Surg.* 2023;**46**(1):405–411. doi: 10.1016/j.asjsur.2022.05.002.

24. Yang H, Zhang Q, Gao K, et al. Evaluating modified ultrasound-guided serratus anterior plane block for enhanced postoperative recovery in thoracoscopic lobectomy patients. *Med Sci Monit.* 2024;**30**:e942757. doi: 10.12659/MSM.942757.

25. van den Broek RJC, Koopman JSHA, Postema JMC, et al. Continuous erector spinae plane block versus thoracic epidural analgesia in video-assisted thoracic surgery: a study protocol for a prospective randomized open label non-inferiority trial. *Trials.* 2021;**22**(1):321. doi: 10.1186/s13063-021-05275-9.

26. Wang J, Huang J, Yang S, et al. Pharmacokinetics and safety of esketamine in chinese patients undergoing painless gastroscopy in comparison with ketamine: a randomized, open-label clinical study. *Drug Des Devel Ther.* 2019 Dec 6;**13**:4135–4144. doi: 10.2147/DDDT.S224553.

27. Zhang Y, Cui F, Ma JH, Wang DX. Mini-dose esketamine-dexmedetomidine combination to supplement analgesia for patients after scoliosis correction surgery: a double-blind randomised trial. *Br J Anaesth.* 2023;**131**(2):385–396. doi: 10.1016/j.bja.2023.05.001.

28. Zhang J, Jia D, Li W, Li X, Ma Q, Chen X. General anesthesia with S-ketamine improves the early recovery and cognitive function in patients undergoing modified radical mastectomy: a prospective randomized controlled trial. *BMC Anesthesiol.* 2023;**23**(1):214. doi: 10.1186/s12871-023-02161-6.

29. Gerresheim G, Handschu R, Winkler B, et al. Prevention of postoperative delirium. *MMW Fortschr Med.* 2020;**162**(8):50–57.

30. Yao M, Fang B, Yang J, Chen P, Chen F. Esketamine combined with sufentanil versus sufentanil in patient-controlled intravenous analgesia: a meta-analysis. *Front Pharmacol.* 2024;**15**:1247646. doi: 10.3389/fphar.2024.1247646.

31. Xu S, Yang J, Li J et al., Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trail. *BMC Anesthesiol.* 2024;**24**(1):20. doi: 10.1186/s12871-023-02398-1.

32. Zheng L, Zhao J, Zheng L, Jing S, Wang X. Effect of dexmedetomidine on perioperative stress response and immune function in patients with tumors. *Technol Cancer Res Treat.* 2020;**19**:1533033820977542. doi: 10.1177/1533033820977542.

33. Zhang Z, Duan Z, Cui Y. CD8+ T cells in brain injury and neurodegeneration. *Front Cell Neurosci.* 2023;**17**:1281763. doi: 10.3389/fncel.2023.1281763.